Medical management of chronic obstructive pulmonary disease

Chest Surgery Clinics of North America

Volumn 13, Issue 4, 2003, Pages 615-629

  Sciurba, Frank C ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUSPIRONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FORMOTEROL; MUCOLYTIC AGENT; NARCOTIC AGENT; PHOSPHODIESTERASE INHIBITOR; SALMETEROL; THEOPHYLLINE DERIVATIVE; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; EXERCISE TOLERANCE; EXPIRATORY FLOW RATE; HEALTH PROGRAM; HUMAN; MYOPATHY; OSTEOPENIA; OXYGEN THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYMPTOM; TACHYPHYLAXIS;

EID: 0344825997     PISSN: 10523359     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-3359(03)00099-1     Document Type: Review

References (85)

1. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. National Center for Health Statistics. MMWR Surveill Summ 2002;51:1-16.
2. Lopez AD, Murray CC. The global burden of disease, 1990-2000. Nat Med 1998;4:1241-3.
3. Straus SE, McAlister FA, Sackett DL, Deeks JJ, CARE-COAD2 Group. Clinical assessment of the reliability of the examination-chronic obstructive airways disease. Accuracy of history, wheezing, and forced expiratory time in the diagnosis of chronic obstructive pulmonary disease. J Gen Intern Med 2002;17(9):684-8.
4. Schapira RM, Schapira MM, Funahhashi A, McAuliffe TL, Varkey B. The value of the forced expiratory time in the physical diagnosis of obstructive airways disease. JAMA 1993;270(6): 731-6.
5. GOLD. Global initiative for chronic obstructive lung disease. Washington DC: National Institutes of Health; 2003 updated.
6. American Thoracic Society. Standardization of spirometry-1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
7. Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education Program. Chest 2000; 117(4):1146-61.
8. Smith HR, Irvin CG, Chemiack RM. The utility of spirometry in the diagnosis of reversible airways obstruction. Chest 1992;101:1577-81.
9. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:770-7.
10. Owens GR, Rogers RM, Pennock BE, Levin D. The diffusing capacity as a predictor of arterial oxygen desaturation during exercise in patients with chronic obstructive pulmonary disease. N Engl J Med 1984;310(19):1218-21.
11. American Thoracic Society/American College of Chest Physicians Statement on Cardiopulmonary Exercise Testing. Am J Respir Crit Care Med 2003;167:211-77.
12. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to the mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003;167(4):544-9.
13. NETT Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059-73.
14. NHLBI. Registry for patients with severe deficiency of alpha 1-antitrypsin. Bethesda, MD: National Institutes of Health; 1991.
15. 1. The Lung Health Study. JAMA 1994;272:1497-505.
16. The tobacco use and dependence clinical practice guideline panel, staff, and consortium representatives. A clinical practice guide for treating tobacco use and dependence. JAMA 2000;28: 3244-54.
17. Dennis R, Maldonado D, Norman S, Baena E, Martinez G. Woodsmoke exposure and risk for obstructive airways disease among women. Chest 1996;109:115-9.
18. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331:778-84.
19. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
20. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
21. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115(4):957-65.
22. Grove A, Lipworth BJ, Reid P, et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996;51:689-93.
23. Meslier N, Racineux JL, Six P, Lockhart A. Diagnostic value of reversibility of chronic airway obstruction to separate asthma from chronic bronchitis: a statistical approach. Eur Respir J 1989; 2:497-505.
24. Kesten S, Rebuck AS. Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest 1994;105:1042-5.
25. Tobin MJ. Respiratory muscles in disease. Clin Chest Med 1988;9:263-86.
26. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:967-75.
27. O'Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 2001;18:914-20.
28. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161(4 Pt 1):1136-42.
29. COMBIVENT. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994;105(5):1411-9.
30. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999;159(2):156-60.
31. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byme AM, Thomson MH, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-84.
32. Rennard SI, Anderson W, Zu WR, et al. Use of long-acting inhaled beta(2)-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1087-92.
33. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997;112(2):336-40.
34. Ayers ML, Mejia R, Ward J, et al. Effectiveness of salmeterol versus ipratropium bromide on external dyspnoea in COPD. Eur Respir J 2001;17:1132-7.
35. Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114:411-5.
36. Rogers RM, Owens GR, Pennock BE. The pendulum swings again. Toward a rational use of theophylline. Chest 1985;87(3):280-2.
37. Sichletidis L, Kottakis J, Marcou S, et al. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int J Clin Pract 1999;53:185-8.
38. van Noord JA, de Munck DR, Bantje TA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15:878-85.
39. Cazzola M, DiLorenzo G, DiPerna F, et al. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest 2000;118:1576-81.
40. Zu Wallach RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1661-70.
41. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166(8):1084-91.
42. Calverley P, Pauwels R, Vesbo J, Jones P, Pride N, Gulsvik A, et al. Trial of Inhaled Steroids and long-acting beta2 agonists study group (Tristan). Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease; a randomised controlled trial. Lancet 2003; 361(9356):449-56.
43. Schols AM, Wesseling G, Kester AD, et al. Dose dependent increased mortality risks in COPD patients treated with oral glucocorticoids. Eur Respir J 2001;17:337-42.
44. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113(1):59-65.
45. Wise R, Connett J, Weinmann G, Scanlon P, Skeans M. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseases. N Engl J Med 2000; 343:1902-9.
46. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320(7245): 1297-303.
47. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340(25): 1948-53.
48. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353(9167):1819-23.
49. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group (ICSG). Lancet 1998;351(9105):773-80.
50. Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 1999;93(3):161-6.
51. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the does matter? Eur Respir J 2003;21(2):260-6.
52. Soriano JB, Vesbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002;20(4): 819-25.
53. Suissa S. Effectiveness of inhaled corticosteriods in chronic obstructive pulmonary disease. Immortal time bais in observational studies. Am J Respir Crit Care Med 2003;168:49-53.
54. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BJM 2001;322(7297):1271-4.
55. Poole PJ, Veale AG, Black PN. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1877-80.
56. Rapoport DM, Greenberg HE, Goldring RM. Differing effects of the anxiolytic agents buspirone and diazepam on control of breathing. Clin Pharmacol Ther 1991;49(4):394-401.
57. Argyropoulou P, Patakas D, Koukou A, Vasiliadis P, Georgopoulos D. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration [Herrlisheim] 1993;60(4):216-20.
58. Barbera JA, Roger N, Rocca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996;347:436-40.
59. Barnes PJ. New treatments for COPD. Nat Rev Drug Discov 2002;1(6):437-46.
60. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391-8.
61. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;1: 681-6.
62. Somfay A, Porszasz J, Lee SM, Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 2001;18(1):77-84.
63. National Emphysema Treatment Trial Research Group. Rationale and design of the National Emphysema Treatment Trial (NETT): a prospective randomized trial of lung volume reduction surgery. J Thorac Cardiovas Surg 1999;118:518-28.
64. American Thoracic Society. Pulmonary rehabilitation-1999. Am J Respir 1999;159(5 Pt 1): 1666-82.
65. Carter R, Nicotra B, Blevins W, Holiday D. Altered exercise gas exchange and cardiac function in patients with mild chronic obstructive pulmonary disease. Chest 1993;103:745-50.
66. Lacasse Y, Wong E, Guyatt GH, King D, Cook DJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 1996;348(9035):1115-9.
67. Guell R, Casan P, Belda J, Sangenis M, Morante F, Guyatt GH, et al. Long-term effects of outpatient rehabilitation of COPD: a randomized trial. Chest 2000;117(4):976-83.
68. Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance after pulmonary rehabilitation in chronic lung disease. A randomized trial. Am J Respir Crit Care Med 2003;167:880-8.
69. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomized controlled trial. Lancet 2000;355(9201):362-8.
70. MacFarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 1993;341: 511-4.
71. Codosh S, McCarty J, Farkas S, Drehobl M, Tosiello R, Shan M, et al. Randomized double-blind study of ciprofloxacin and cerfuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 1998;27:722-9.
72. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonization and the frequency, character, and severity of COPD exacerbations. Thorax 2002;57(9):759-64.
73. Donaldson GC, Seemungal TA, Bohowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57(10):847-52.
74. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161(5):1608-13.
75. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157(5 Pt 1):1418-22.
76. Doll H, Grey-Amante P, Duprat-Lomon I, Sagnier PP, Thate-Waschke I, Lorenz J, et al. Quality of life in acute exacerbation of chronic bronchitis: results from a German population study. Respir Med 2002;96(1):39-51.
77. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154(2Pt 1): 407-12.
78. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999;340(25):1941-7.
79. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196-204.
80. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273(12):957-60 [comment JAMA 1995;274(14): 1131-2].
81. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273(12):957-60 [comment JAMA 1995;274(14): 1131-2].
82. Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999;116(1):40-6.
83. Flaherty KR, Saint S, Fendrick AM, Martinez FJ. The spectrum of acute bronchitis. Using baseline factors to guide empirical therapy. Postgrad Med 2001;109(2):39-47.
84. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995;333:817-22.
85. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomized controlled trial. Lancet 2000;355:1931-5.